209 related articles for article (PubMed ID: 38693123)
1. Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma.
Joo V; Abdelhamid K; Noto A; Latifyan S; Martina F; Daoudlarian D; De Micheli R; Pruijm M; Peters S; Hullin R; Gaide O; Pantaleo G; Obeid M
Nat Commun; 2024 Apr; 15(1):3664. PubMed ID: 38693123
[TBL] [Abstract][Full Text] [Related]
2. Complete and Sustained Remission of Metastatic Cutaneous Squamous Cell Carcinoma in a Liver Transplant Patient Treated With Talimogene Laherparepvec.
Nguyen TA; Offner M; Hamid O; Zumsteg ZS; Gharavi NM
Dermatol Surg; 2021 Jun; 47(6):820-822. PubMed ID: 32897942
[No Abstract] [Full Text] [Related]
3. mTOR Inhibitor Therapy Diminishes Circulating CD8+ CD28- Effector Memory T Cells and Improves Allograft Inflammation in Belatacept-refractory Renal Allograft Rejection.
Castro-Rojas CM; Godarova A; Shi T; Hummel SA; Shields A; Tremblay S; Alloway RR; Jordan MB; Woodle ES; Hildeman DA
Transplantation; 2020 May; 104(5):1058-1069. PubMed ID: 31415033
[TBL] [Abstract][Full Text] [Related]
4. Different in vitro proliferation and cytokine-production inhibition of memory T-cell subsets after calcineurin and mammalian target of rapamycin inhibitors treatment.
Merino D; San Segundo D; Medina JM; Rodrigo E; Asensio E; Irure J; Fernández-Fresnedo G; Arias MA; López-Hoyos M
Immunology; 2016 Jun; 148(2):206-15. PubMed ID: 26931075
[TBL] [Abstract][Full Text] [Related]
5. Effector Antitumor and Regulatory T Cell Responses Influence the Development of Nonmelanoma Skin Cancer in Kidney Transplant Patients.
Crespo E; Fernandez L; Lúcia M; Melilli E; Lauzurica R; Penin RM; Quer A; Luque S; Quero M; Manonelles A; Torras J; Cruzado JM; Cañas L; Grinyó JM; Bestard O
Transplantation; 2017 Sep; 101(9):2102-2110. PubMed ID: 28403126
[TBL] [Abstract][Full Text] [Related]
6. CXCR5 + CD8 + T Cell-mediated Suppression of Humoral Alloimmunity and AMR in Mice Is Optimized With mTOR and Impaired With Calcineurin Inhibition.
Han JL; Zimmerer JM; Zeng Q; Chaudhari SR; Hart M; Satoskar AA; Abdel-Rasoul M; Breuer CK; Bumgardner GL
Transplantation; 2024 Mar; 108(3):679-692. PubMed ID: 37872660
[TBL] [Abstract][Full Text] [Related]
7. Talimogene laherparepvec (T-VEC) in advanced melanoma: complete response in a heart and kidney transplant patient. A case report.
Ressler J; Silmbrod R; Stepan A; Tuchmann F; Cicha A; Uyanik-Ünal K; Hoeller C
Br J Dermatol; 2019 Jul; 181(1):186-189. PubMed ID: 30776080
[TBL] [Abstract][Full Text] [Related]
8. Prompt response of advanced cutaneous squamous cell carcinoma to cemiplimab in a kidney transplant patient receiving treatment with everolimus.
Gambichler T; Hessam S; Lüttringhaus T; Boms S
Clin Exp Dermatol; 2022 Mar; 47(3):608-609. PubMed ID: 34767651
[TBL] [Abstract][Full Text] [Related]
9. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Höcker B; Tönshoff B
Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
[TBL] [Abstract][Full Text] [Related]
10. Oscillatory mTOR inhibition and Treg increase in kidney transplantation.
Sabbatini M; Ruggiero G; Palatucci AT; Rubino V; Federico S; Giovazzino A; Apicella L; Santopaolo M; Matarese G; Galgani M; Terrazzano G
Clin Exp Immunol; 2015 Nov; 182(2):230-40. PubMed ID: 26077103
[TBL] [Abstract][Full Text] [Related]
11. Early Everolimus Initiation Fails to Counteract the Cytotoxic Response Mediated by CD8
Díaz-Molina B; Diaz-Bulnes P; Carvajal Palao R; Bernardo MJ; Rodriguez RM; Corte-Iglesias V; Moris de la Tassa C; Lambert JL; Suarez-Alvarez B
Front Immunol; 2018; 9():2181. PubMed ID: 30319636
[TBL] [Abstract][Full Text] [Related]
12. Immunoexpression of perforin and granzyme B on infiltrating lymphocytes in human renal acute allograft rejection.
Wagrowska-Danilewicz M; Danilewicz M
Nefrologia; 2003; 23(6):538-44. PubMed ID: 15002789
[TBL] [Abstract][Full Text] [Related]
13. mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.
Fernandes-Silva G; Ivani de Paula M; Rangel ÉB
Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):367-385. PubMed ID: 27659512
[TBL] [Abstract][Full Text] [Related]
14. mTOR inhibition improves mitochondria function/biogenesis and delays cardiovascular aging in kidney transplant recipients with chronic graft dysfunction.
Infante B; Bellanti F; Correale M; Pontrelli P; Franzin R; Leo S; Calvaruso M; Mercuri S; Netti GS; Ranieri E; Brunetti ND; Grandaliano G; Gesualdo L; Serviddio G; Castellano G; Stallone G
Aging (Albany NY); 2021 Mar; 13(6):8026-8039. PubMed ID: 33758105
[TBL] [Abstract][Full Text] [Related]
15. Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report.
Owonikoko TK; Kumar M; Yang S; Kamphorst AO; Pillai RN; Akondy R; Nautiyal V; Chatwal MS; Book WM; Sahu A; Sica GL; Ahmed R; Ramalingam SS
Cancer Immunol Immunother; 2017 Jan; 66(1):45-50. PubMed ID: 27771741
[TBL] [Abstract][Full Text] [Related]
16. mTOR Inhibition Suppresses Posttransplant Alloantibody Production Through Direct Inhibition of Alloprimed B Cells and Sparing of CD8+ Antibody-Suppressing T cells.
Avila CL; Zimmerer JM; Elzein SM; Pham TA; Abdel-Rasoul M; Bumgardner GL
Transplantation; 2016 Sep; 100(9):1898-906. PubMed ID: 27362313
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive effects of DTCM-G, a novel inhibitor of the mTOR downstream signaling pathway.
Shibasaki S; Yamashita K; Goto R; Wakayama K; Tsunetoshi Y; Zaitsu M; Igarashi R; Haga S; Ozaki M; Umezawa K; Todo S
Transplantation; 2013 Feb; 95(4):542-50. PubMed ID: 23269193
[TBL] [Abstract][Full Text] [Related]
18. Conversion to Belatacept based regimen does not change T-cell phenotype and function in renal transplantation.
Matz M; Fabritius K; Liu J; Lorkowski C; Brakemeier S; Unterwalder N; Dürr M; Mashreghi MF; Neumayer HH; Budde K
Transpl Immunol; 2015 Nov; 33(3):176-84. PubMed ID: 26478531
[TBL] [Abstract][Full Text] [Related]
19. T follicular helper and memory cell responses and the mTOR pathway in murine heart transplantation.
Xie A; Yan H; Fu J; He A; Xiao X; Li XC; Chen W
J Heart Lung Transplant; 2020 Feb; 39(2):134-144. PubMed ID: 31831210
[TBL] [Abstract][Full Text] [Related]
20. Correlation between circulating endothelial progenitor cell function and allograft rejection in heart transplant patients.
Sathya CJ; Sheshgiri R; Prodger J; Tumiati L; Delgado D; Ross HJ; Rao V
Transpl Int; 2010 Jun; 23(6):641-8. PubMed ID: 20102553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
